Abatacept for Patients With Inflammatory Arthritis Associated With Sjogren's Syndrome: an Open-Label Phase II Study
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Polyarthritis; Rheumatoid arthritis; Sjogren's syndrome
- Focus Registrational; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jan 2017 Planned End Date changed from 1 Apr 2015 to 1 Oct 2014.
- 05 Jan 2017 Planned primary completion date changed from 1 Apr 2015 to 1 Oct 2014.